The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver.
Shares of Biogen were up 4.5% in afternoon trading. The approval applies to an under-the-skin formulation of the drug branded as Leqembi. Until now, patients starting treatment received the drug through intravenous infusions, typically given at a clinic, and could later switch to maintenance treatment after 18 months.
